MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This study is testing a new type of treatment that uses a modified virus to help the immune system identify and attack specific blood cancers that have returned or stopped responding to standard treatments. By using a virus designed to target cancer cells while protecting healthy ones, researchers hope to find a more effective way to fight difficult-to-treat diseases like multiple myeloma and various lymphomas.

This trial is for adults (18+) who have been diagnosed with certain types of blood cancer—such as multiple myeloma, acute myeloid leukemia, or specific T-cell lymphomas—that have not responded to or have returned after previous standard treatments. Participants must also meet specific medical criteria, such as not having other uncontrolled infections like tuberculosis or hepatitis.

Participants will receive the modified virus treatment, sometimes combined with other medications like chemotherapy or immunotherapy, to see how well they work and to monitor for side effects. You will undergo regular health checks, including blood tests, bone marrow samples, and imaging scans like X-rays or heart scans, to track how the treatment is affecting both the cancer and your body.

The study is currently recruiting patients and is being conducted at medical centers in Scottsdale, Arizona, and Rochester, Minnesota. If you are interested, your clinical team can help you determine if your specific medical history fits the study requirements.